A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions

Head and Neck Cancers

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200mg, IV, 3 cycles

DRUG

Cisplatin

cisplatin 75mg/m2, IV, 3 cycles

DRUG

Nab-paclitaxel

Nab-paclitaxel 260mg, IV, 3 cycles

All Listed Sponsors

lead

Beijing Tongren Hospital

OTHER